209 related articles for article (PubMed ID: 19570652)
1. Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.
Klejbor I; Kucinski A; Wersinger SR; Corso T; Spodnik JH; Dziewiatkowski J; Moryś J; Hesse RA; Rice KC; Miletich R; Stachowiak EK; Stachowiak MK
Schizophr Res; 2009 Sep; 113(2-3):308-21. PubMed ID: 19570652
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice.
Klejbor I; Myers JM; Hausknecht K; Corso TD; Gambino AS; Morys J; Maher PA; Hard R; Richards J; Stachowiak EK; Stachowiak MK
J Neurochem; 2006 Jun; 97(5):1243-58. PubMed ID: 16524369
[TBL] [Abstract][Full Text] [Related]
3. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
4. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia.
Kucinski A; Syposs C; Wersinger S; Bencherif M; Stachowiak MK; Stachowiak EK
Schizophr Res; 2012 Apr; 136(1-3):82-7. PubMed ID: 22285656
[TBL] [Abstract][Full Text] [Related]
5. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K; Price DL; Bonhaus DW
Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
[TBL] [Abstract][Full Text] [Related]
7. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice.
Barr AM; Lehmann-Masten V; Paulus M; Gainetdinov RR; Caron MG; Geyer MA
Neuropsychopharmacology; 2004 Feb; 29(2):221-8. PubMed ID: 14603268
[TBL] [Abstract][Full Text] [Related]
8. Repetitive grooming and sensorimotor abnormalities in an ephrin-A knockout model for Autism Spectrum Disorders.
Wurzman R; Forcelli PA; Griffey CJ; Kromer LF
Behav Brain Res; 2015 Feb; 278():115-28. PubMed ID: 25281279
[TBL] [Abstract][Full Text] [Related]
9. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).
Martin P; Waters N; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1997; 104(4-5):561-4. PubMed ID: 9295186
[TBL] [Abstract][Full Text] [Related]
10. Glutamic acid decarboxylase 67 haplodeficiency in mice: consequences of postweaning social isolation on behavior and changes in brain neurochemical systems.
Nullmeier S; Elmers C; D'Hanis W; Sandhu KVK; Stork O; Yanagawa Y; Panther P; Schwegler H
Brain Struct Funct; 2020 Jul; 225(6):1719-1742. PubMed ID: 32514634
[TBL] [Abstract][Full Text] [Related]
11. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
Barr AM; Powell SB; Markou A; Geyer MA
Neuropharmacology; 2006 Sep; 51(3):457-65. PubMed ID: 16762376
[TBL] [Abstract][Full Text] [Related]
12. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats.
Varty GB; Bakshi VP; Geyer MA
Neuropsychopharmacology; 1999 Apr; 20(4):311-21. PubMed ID: 10088132
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and dopamine interactions in psychosis prevention.
Richtand NM; McNamara RK
Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
[TBL] [Abstract][Full Text] [Related]
14. Role of prefrontal cortical 5-HT
Mitazaki S; Nakagawasai O; Onogi H; Watanabe K; Takahashi K; Tan-No K; Quirion R; Srivastava LK; Tadano T
Behav Brain Res; 2020 Jan; 377():112226. PubMed ID: 31521737
[TBL] [Abstract][Full Text] [Related]
15. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
Meltzer HY; Massey BW; Horiguchi M
Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia.
Guo X; Hamilton PJ; Reish NJ; Sweatt JD; Miller CA; Rumbaugh G
Neuropsychopharmacology; 2009 Jun; 34(7):1659-72. PubMed ID: 19145222
[TBL] [Abstract][Full Text] [Related]
17. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Stahl SM
CNS Spectr; 2016 Oct; 21(5):355-359. PubMed ID: 27686027
[TBL] [Abstract][Full Text] [Related]
19. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
Adams W; van den Buuse M
Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
[TBL] [Abstract][Full Text] [Related]
20. Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice.
Lairez O; Cognet T; Schaak S; Calise D; Guilbeau-Frugier C; Parini A; Mialet-Perez J
J Neural Transm (Vienna); 2013 Jun; 120(6):927-35. PubMed ID: 23543114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
